37 results match your criteria: "University of Ferrara and Azienda Ospedaliero-Universitaria S.Anna[Affiliation]"

Objective: Glucocorticoid (GC) tapering and withdrawal to reduce damage represents a key aspect of the European Alliance of Associations for Rheumatology (EULAR) SLE recommendations. However, optimal strategies for relapse-free GC cessation remain ill-defined. We characterised clinical predictors and their combined effect on flares in patients with SLE who discontinued GC.

View Article and Find Full Text PDF

Background: Neuropsychiatric symptoms in SLE and other systemic autoimmune rheumatic diseases (SARDs) are challenging to diagnose, attribute and manage. We investigated the timings of onset of a broad range of neuropsychiatric (NP) symptoms in relation to timing of SLE onset. In addition, we explored whether NP symptoms may be a prodrome to SARD onset and to subsequent flares.

View Article and Find Full Text PDF

Objective: Subjects with subclinical psoriatic arthritis (PsA), defined as the presence of arthralgia in psoriasis (PsO), are at higher risk of PsA but scant real-world data exist. Our aims were to (1) estimate the probability of PsA development in subclinical PsA, (2) characterise subclinical PsA symptoms and (3) determine the clinical patterns at PsA diagnosis.

Methods: Patients with PsO, mainly subclinical PsA, were evaluated longitudinally in two European cohorts.

View Article and Find Full Text PDF

Systemic lupus erythematosus: one year in review 2024.

Clin Exp Rheumatol

March 2024

Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.

Article Synopsis
  • - Systemic lupus erythematosus (SLE) is a complex autoimmune disease known for diverse symptoms affecting multiple body systems, and its clinical course can vary greatly among patients.
  • - Recent research advancements have improved SLE management and treatment, but many challenges—like understanding its causes and effective therapies—still exist for both patients and healthcare providers.
  • - The 2023 updates focus on important topics such as biomarkers, clinical outcomes, co-existing conditions, and new treatment strategies based on real-world evidence.
View Article and Find Full Text PDF

Objective: Attribution of neuropsychiatric symptoms in systemic lupus erythematosus (SLE) relies heavily on clinician assessment. Limited clinic time, variable knowledge, and symptom under-reporting contributes to discordance between clinician assessments and patient symptoms. We obtained attributional data directly from patients and clinicians in order to estimate and compare potential levels of direct attribution to SLE of multiple neuropsychiatric symptoms using different patient-derived measures.

View Article and Find Full Text PDF

Background: Inflammatory arthritis (IAs), such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA), are characterized by the presence of chronic synovitis. The Krenn's synovitis score (KSS), a simple tool detectable by haematoxylin/eosin staining of synovial biopsy samples, allows the discrimination between high-grade and low-grade synovitis. The aim of this study was to identify the clinical associations of KSS and to evaluate the relationship between high-grade synovitis and treatment response in IA patients.

View Article and Find Full Text PDF

Objectives: Treatment targets in systemic lupus erythematosus (SLE) have been validated in unselected-in terms of severity-cohorts, which limits their generalisability. We assessed remission (Definition of Remission in SLE (DORIS)) and Lupus Low Disease Activity State (LLDAS) in a historical cohort of 348 patients with active moderate-to-severe disease and median follow-up of 5 years.

Methods: Active SLE was defined as Physician Global Assessment ≥1.

View Article and Find Full Text PDF

Tofacitinib restores psoriatic arthritis fibroblast-like synoviocytes function via autophagy and mitochondrial quality control modulation.

J Autoimmun

February 2024

Department of Medical Sciences, Section of Experimental Medicine, University of Ferrara, Laboratory for Technologies of Advanced Therapies (LTTA), Ferrara, Italy. Electronic address:

Objectives: To evaluate the in vitro effect of tofacitinib on autophagy activity of psoriatic arthritis (PsA) fibroblast-like synoviocytes (FLS), and to confirm its activity on inflammatory and invasive properties of FLS and synovial cells, deepening the impact on mitochondrial function.

Methods: FLS, peripheral blood mononuclear cells (PBMCs), and synovial cells from active PsA patients were cultured with tofacitinib 1 μM or vehicle control for 24 h. Autophagy was measured by Western blot and by fluorescence microscopy.

View Article and Find Full Text PDF

Novel insights into the management of rheumatoid arthritis: one year in review 2023.

Clin Exp Rheumatol

November 2023

School of Medicine and Surgery, University of Milano-Bicocca, Milan; and Epidemiology Unit, Italian Society for Rheumatology, Milan, Italy.

Article Synopsis
  • Recent findings from 2022 for rheumatoid arthritis (RA) management emphasize the importance of customizing treatment based on individual patient characteristics and response to medications.
  • Research into biomarkers and remote care applications highlights the shift towards precision medicine and a more patient-centered approach in treating RA.
  • Updated guidelines from new vaccination developments and literature also impact the management of RA-related issues, such as interstitial lung disease and pregnancy.
View Article and Find Full Text PDF

Systemic lupus erythematosus: one year in review 2023.

Clin Exp Rheumatol

May 2023

Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.

Article Synopsis
  • - Systemic lupus erythematosus (SLE) is a long-lasting autoimmune disorder that can cause various symptoms and occurs in cycles of flare-ups and remission.
  • - Recent research has revealed new information on SLE's underlying causes, potential biomarkers for diagnosis, and innovative treatment approaches to better manage the disease.
  • - The review focuses on significant findings from 2022 regarding SLE, including insights into associated health issues and the reproductive health of individuals affected by the disease.
View Article and Find Full Text PDF

A number of studies have suggested that human herpesvirus 6A (HHV-6A) may play a role in multiple sclerosis (MS). Three possible hypotheses have been investigated: (1) U24 from HHV-6A (U24-6A) mimics myelin basic protein (MBP) through analogous phosphorylation and interaction with Fyn-SH3; (2) U24-6A affects endocytic recycling by binding human neural precursor cell (NPC) expressed developmentally down-regulated protein 4-like WW3* domain (hNedd4L-WW3*); and (3) MS patients who express Killer Cell Immunoglobulin Like Receptor 2DL2 (KIR2DL2) on natural killer (NK) cells are more susceptible to HHV-6 infection. In this contribution, we examined the validity of these propositions by investigating the interactions of U24 from HHV-6B (U24-6B), a variant less commonly linked to MS, with Fyn-SH3 and hNedd4L-WW3* using heteronuclear single quantum coherence (HSQC) nuclear magnetic resonance (NMR) titrations and isothermal titration calorimetry (ITC).

View Article and Find Full Text PDF

Objectives: Gout treatment is largely suboptimal in clinical practice. We aimed to assess the predictors of disease-activity at 12 months in a real-life setting.

Methods: Consecutive patients referred to Rheumatology Units for suspected acute crystal-induced arthritis were enrolled in a multicentre-cohort study.

View Article and Find Full Text PDF

New evidence for the treatment of rheumatoid arthritis (RA) has emerged during the last year. Specifically, updated guidelines on pharmacological and non-pharmacological management of RA have emphasised the necessity of global patient's care, and have shifted the role of some older drugs, such as glucocorticoids and methotrexate. In addition, the long-term safety of Janus kinase inhibitors was investigated and reinforced.

View Article and Find Full Text PDF
Article Synopsis
  • This study explored the relationship between low-dose glucocorticoids (GCs) and mortality in patients with early arthritis, specifically rheumatoid arthritis (RA) or undifferentiated arthritis, using linked clinical and administrative data.
  • A total of 449 patients were enrolled, with a follow-up period averaging about 104 months; 11.36% of participants died during the study.
  • The analysis indicated that low-dose GCs did not significantly predict mortality, regardless of dosage (≤7.5 mg/day or >7.5 mg/day), suggesting no clear impact on overall survival in these patients.
View Article and Find Full Text PDF

In multiple sclerosis (MS), there is a possible relationship with viral infection, evidenced by clinical evidence of an implication of infectious events with disease onset and/or relapse. The aim of this research is to study how human herpesvirus (HHVs) infections might dysregulate the innate immune system and impact autoimmune responses in MS. We analyzed 100 MS relapsing remitting patients, in the remission phase, 100 healthy controls and 100 subjects with other inflammatory neurological diseases (OIND) (neuro-lupus) for their immune response to HHV infection.

View Article and Find Full Text PDF

An Italian Multicenter Study on Anti-NXP2 Antibodies: Clinical and Serological Associations.

Clin Rev Allergy Immunol

October 2022

Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.

The identification of anti-NXP2 antibodies is considered a serological marker of dermatomyositis (DM), with calcinosis, severe myositis and, in some reports, with cancer. Historically, these associations with anti-NXP2 antibodies have been detected by immunoprecipitation (IP), but in the last few years commercial immunoblotting assays have been released. The aim of this collaborative project was to analyse the clinical features associated to anti-NXP2 antibodies, both with commercial line blot (LB) and IP.

View Article and Find Full Text PDF

One year in review 2022: systemic lupus erythematosus.

Clin Exp Rheumatol

January 2022

Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.

Article Synopsis
  • Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple body systems and presents with a wide range of symptoms.
  • Recent research has provided new information on the causes, biomarkers, and clinical features of SLE, leading to potential advancements in treatment options.
  • The review aims to summarize the key findings related to SLE that emerged in 2021, building upon previous annual reviews.
View Article and Find Full Text PDF

Objective: The optimal choice of a second biological disease-modifying anti-rheumatic drug (bDMARD) after failure with first line tumour necrosis factor inhibitor (TNFi) represents a critical therapeutic challenge. This study aims to evaluate the persistence with treatment using second line bDMARDs with different mechanisms of action in rheumatoid arthritis (RA) patients with inadequate response to first line TNFi.

Method: A retrospective cohort study on administrative healthcare databases was conducted.

View Article and Find Full Text PDF

In psoriatic arthritis (PsA) patients with concomitant chronic widespread pain, the differential diagnosis with fibromyalgia syndrome (FMS) can be challenging. We evaluated whether ultrasound (US) examination of entheseal sites can distinguish pain from (PsA) enthesitis versus FMS. PsA and FMS patients underwent clinical evaluation and gray-scale (GS; B-mode) and power Doppler (PD) US examination of the entheses.

View Article and Find Full Text PDF

Rheumatoid arthritis (RA) is associated with an increase in cardiovascular (CV) risk. This issue maybe not only explained by a genetic component, as well as by the traditional CV risk factors, but also by an underestimation and undertreatment of concomitant CV comorbidities. This was a retrospective matched-cohort analysis in the Italian RA real-world population based on the healthcare-administrative databases to assess the CV risk factors and incidence of CV events in comparison with the general population.

View Article and Find Full Text PDF

Objectives: We aimed to assess the performance of the 2015 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) gout classification criteria in an Italian cohort of patients with crystal-induced arthritis stratified by disease duration and gender in a real-life setting.

Methods: Consecutive patients referred to Rheumatology Units for suspected acute crystal-induced arthritis were enrolled in a multicentre cohort study by the Italian Society of Rheumatology which was designed to improve the management of crystal-induced arthritis (ATTACk). To test the performance of the criteria (sensitivity and specificity), the presence of monosodium urate (MSU) crystals in synovial fluid (SF) was used as gold standard.

View Article and Find Full Text PDF

One year in review 2021: novelties in the treatment of rheumatoid arthritis.

Clin Exp Rheumatol

July 2021

Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna, Cona, Ferrara, and Epidemiology Unit, Italian Society for Rheumatology, Milan, Italy.

Management of rheumatoid arthritis (RA) has evolved over the years as a result of better understanding of the role of different therapeutic strategies, as well as following an increasing availability of new disease-modifying antirheumatic drugs. However, the role of patients in sharing decisions, as well as the rules informing precision medicine or the principles to follow in case of specific comorbidities or extra-articular manifestations are still areas for improvement. Moreover, in 2020, the novel Coronavirus disease-19 outbreak has completely changed many attitudes in terms of assessment and treatment paradigms in most clinical diseases, including RA.

View Article and Find Full Text PDF
Article Synopsis
  • Antiphospholipid antibodies (aPL) can lead to fetal loss, and while some studies suggest low complement levels (C3/C4) may be linked to pregnancy complications, the results aren't universally agreed upon.
  • A multicenter study involving 503 pregnancies examined the relationship between preconception complement levels and adverse pregnancy outcomes (APO) in women with antiphospholipid syndrome (APS) and aPL carriers.
  • The study found that low C3/C4 levels before pregnancy were significantly associated with higher rates of pregnancy loss, particularly in women who tested positive for triple aPL, indicating that measuring complement levels could help identify those at risk for pregnancy complications.
View Article and Find Full Text PDF

One year in review 2021: systemic lupus erythematosus.

Clin Exp Rheumatol

April 2021

Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.

Article Synopsis
  • In 2020, significant research was published on systemic lupus erythematosus (SLE), particularly regarding genetic factors that play a role in its development.
  • The review highlights novel therapeutic targets like IL-23, IL-17, and JAKs, as well as important biomarkers for diagnosis and prognosis.
  • It also discusses new treatment options, especially belimumab and anifrolumab, and addresses factors affecting patients' perception of their disease and overall quality of life.
View Article and Find Full Text PDF

Objectives: Although neuropsychiatric involvement in SLE (NPSLE) is one of the most complex and troubling manifestations of the disease, validated outcome instruments to be used as sensitive endpoints in controlled clinical trials are lacking. We performed a systematic literature review (SLR) to identify outcome measurement instruments and domains used to assess NPSLE.

Methods: The Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines were used.

View Article and Find Full Text PDF